^
Association details:
| Biomarker: | ALK I1171T |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Excerpt:
All those patients with tumors harboring common ALK resistance mutations, including E1129V, L1196M, C1156Y, I1171T and F1174V, had partial responses with ceritinib, while a patient with G1202R did not respond
DOI:
10.2147/DDDT.S113500
Trial ID:
Source:
Title:
Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib
Excerpt:
We identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib. Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response.
DOI:
10.1158/1078-0432.CCR-14-1511
